Peak early‐phase enhancement ratio on contrast‐enhanced MRI to differentiate chromophobe renal cell carcinoma from oncocytoma
Differentiating chRCCs from oncocytomas using PEER measurements obtained from contrast-enhanced MRI is feasible and reproducible between radiologists. We identified an accurate range for PEER cutoff values (0.98 to 1.05) requiring validation and adjustment in additional cohorts to maintain high sensitivity for detecting chRCC and negative predictive value. Using MRI PEER to evaluate oncocytic tumours with a differential diagnosis of chRCC versus oncocytoma based on biopsy pathology may help avoid unnecessary intervention for oncocytomas.
Authors
- Davide Bova
- Marcus Lee Quek (ORCID: https://orcid.org/0000-0002-6301-3955)
- Hiten D. Patel (ORCID: https://orcid.org/0000-0003-4028-010X)
- Gopal Nand Gupta (ORCID: https://orcid.org/0000-0002-8502-708X)
- Deanna L. Thorson (ORCID: https://orcid.org/0009-0002-8649-3020)
- Maria M. Picken (ORCID: https://orcid.org/0000-0002-8065-6178)
Institutions
- Northwestern University (US)
- Loyola University Medical Center (US)
- Jesse Brown VA Medical Center (US)
Publication Details
- Journal
- BJUI Compass
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/bco2.70017
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52